Heron Therapeutics, Inc. (HRTX)
HRTX Stock Price Chart
Explore Heron Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze HRTX price movements and trends.
HRTX Company Profile
Discover essential business fundamentals and corporate details for Heron Therapeutics, Inc. (HRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Aug 1987
Employees
122.00
Website
https://www.herontx.comCEO
Craig Alexander Collard
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
HRTX Financial Timeline
Browse a chronological timeline of Heron Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.01, while revenue estimate is $39.03M.
Earnings released on 8 Aug 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $37.20M , missing expectations by -4.75%.
Earnings released on 6 May 2025
EPS came in at $0.01 surpassing the estimated -$0.01 by +200.00%, while revenue for the quarter reached $38.90M , beating expectations by +1.71%.
Earnings released on 27 Feb 2025
EPS came in at $0.02 surpassing the estimated -$0.03 by +166.67%, while revenue for the quarter reached $40.78M , beating expectations by +11.20%.
Earnings released on 12 Nov 2024
EPS came in at -$0.03 falling short of the estimated -$0.03 by -9.09%, while revenue for the quarter reached $42.27M , beating expectations by +13.12%.
Earnings released on 6 Aug 2024
EPS came in at -$0.06 falling short of the estimated -$0.04 by -50.00%, while revenue for the quarter reached $36.02M , missing expectations by -1.63%.
Earnings released on 7 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.08 by +75.00%, while revenue for the quarter reached $34.67M , missing expectations by -3.40%.
Earnings released on 12 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.15 by +53.33%, while revenue for the quarter reached $34.23M , beating expectations by +10.54%.
Earnings released on 14 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.31 by +45.16%, while revenue for the quarter reached $31.43M , beating expectations by +1.60%.
Earnings released on 14 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.23 by -52.17%, while revenue for the quarter reached $31.76M , beating expectations by +0.20%.
Earnings released on 11 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.17 by -58.82%, while revenue for the quarter reached $29.62M , missing expectations by -0.25%.
Earnings released on 23 Mar 2023
EPS came in at -$0.17 surpassing the estimated -$0.25 by +32.00%, while revenue for the quarter reached $30.03M , beating expectations by +11.63%.
Earnings released on 8 Nov 2022
EPS came in at -$0.38 surpassing the estimated -$0.39 by +2.56%, while revenue for the quarter reached $26.56M , missing expectations by -1.49%.
Earnings released on 9 Aug 2022
EPS came in at -$0.55 falling short of the estimated -$0.50 by -10.00%, while revenue for the quarter reached $27.63M , beating expectations by +12.54%.
Earnings released on 9 May 2022
EPS came in at -$0.63 falling short of the estimated -$0.45 by -40.00%, while revenue for the quarter reached $23.46M , beating expectations by +3.76%.
Earnings released on 28 Feb 2022
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $20.66M , missing expectations by -19.86%.
Earnings released on 3 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $23.23M , missing expectations by -8.94%.
Earnings released on 9 Aug 2021
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%, while revenue for the quarter reached $22.44M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.58 falling short of the estimated -$0.57 by -1.75%, while revenue for the quarter reached $20.02M , missing expectations by -21.77%.
Earnings released on 24 Feb 2021
EPS came in at -$0.68 matching the estimated -$0.68, while revenue for the quarter reached $20.61M , beating expectations by +17.14%.
Earnings released on 5 Nov 2020
EPS came in at -$0.64 surpassing the estimated -$0.65 by +1.54%, while revenue for the quarter reached $19.97M , beating expectations by +62.06%.
HRTX Stock Performance
Access detailed HRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.